203 related articles for article (PubMed ID: 15107330)
21. Both a visual and a semiquantitative analysis for differentiating benign from malignant chondrogenic bone tumors using Tc-99m (V) DMSA scintigraphy: a prospective study.
Shinya T; Sato S; Kunisada T; Inai R; Yanai H; Ozaki T; Kanazawa S
Nucl Med Commun; 2015 Aug; 36(8):802-7. PubMed ID: 25932541
[TBL] [Abstract][Full Text] [Related]
22. Tc-99m pentavalent DMSA scintigraphy in myelofibrosis detection.
Koutsikos JT; Velidaki A; Athanasoulis T
Clin Nucl Med; 2006 Dec; 31(12):806-7. PubMed ID: 17117079
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic value of 99mTc-methylene diphosphonate and 99mTc-pentavalent DMSA compared with 99mTc-sestamibi for palpable breast lesions.
Massardo T; Alonso O; Kabasakal L; Llamas-Olier A; Shankar UR; Zhu H; Delgado L; González P; Mut F; Padhy AK
J Nucl Med; 2002 Jul; 43(7):882-8. PubMed ID: 12097457
[TBL] [Abstract][Full Text] [Related]
24. Pentavalent technetium-99m-dimercaptosuccinic acid scintigraphy in renal osteodystrophy.
Higuchi T; Hirano T; Inoue T; Aoki J; Ueki K; Wakamatsu R; Yano S; Naruse T; Endo K
J Nucl Med; 1998 Mar; 39(3):541-3. PubMed ID: 9529307
[TBL] [Abstract][Full Text] [Related]
25. Bone-scan-like pattern with 99Tcm(V)-DMSA scintigraphy in patients with osteomalacia and primary hyperparathyroidism.
Akbunar AT; Orhan B; Alper E
Nucl Med Commun; 2000 Feb; 21(2):181-5. PubMed ID: 10758614
[TBL] [Abstract][Full Text] [Related]
26. Role of technetium-99m N,N-ethylenedicysteine renal scintigraphy in the evaluation of differential renal function and cortical defects.
Buyukdereli G; Guney IB
Clin Nucl Med; 2006 Mar; 31(3):134-8. PubMed ID: 16495730
[TBL] [Abstract][Full Text] [Related]
27. Combined use of 99mTc-sestamibi and 99mTc-V-DMSA in the assessment of chemotherapy effectiveness in patients with multiple myeloma.
Koutsikos J; Athanasoulis T; Anagnostopoulos A; Velidaki A; Passadi M; Dimopoulos MA; Zerva C
J Nucl Med; 2005 Jun; 46(6):978-82. PubMed ID: 15937309
[TBL] [Abstract][Full Text] [Related]
28. 123I-hippuran renal scintigraphy with evaluation of single-kidney clearance for predicting renal scarring after acute urinary tract infection: comparison with (99m)Tc-DMSA scanning.
Imperiale A; Olianti C; Sestini S; Materassi M; Seracini D; Ienuso R; La Cava G
J Nucl Med; 2003 Nov; 44(11):1755-60. PubMed ID: 14602856
[TBL] [Abstract][Full Text] [Related]
29. Potential utility of MRI in the evaluation of children at risk of renal scarring.
Chan YL; Chan KW; Yeung CK; Roebuck DJ; Chu WC; Lee KH; Metreweli C
Pediatr Radiol; 1999 Nov; 29(11):856-62. PubMed ID: 10552069
[TBL] [Abstract][Full Text] [Related]
30. 99mTc depreotide scan compared with 99mTc-MDP bone scintigraphy for the detection of bone metastases and prediction of response to hormonal treatment in patients with breast cancer.
Van Den Bossche B; D'haeninck E; De Winter F; Van Belle S; Dierckx RA; Van De Wiele C
Nucl Med Commun; 2004 Aug; 25(8):787-92. PubMed ID: 15266172
[TBL] [Abstract][Full Text] [Related]
31. Soft-tissue tumors: diagnosis with Tc-99m (V) dimercaptosuccinic acid scintigraphy.
Kobayashi H; Sakahara H; Hosono M; Shirato M; Endo K; Kotoura Y; Yamamuro T; Konishi J
Radiology; 1994 Jan; 190(1):277-80. PubMed ID: 8259419
[TBL] [Abstract][Full Text] [Related]
32. Tc-99m DMSA uptake by metastatic colorectal carcinoma.
Rondogianni P; Koniaris G
Clin Nucl Med; 2004 Aug; 29(8):485-7. PubMed ID: 15249824
[TBL] [Abstract][Full Text] [Related]
33. High false negative rate of Tc-99m MDP whole-body bone scintigraphy in detecting skeletal metastases for patients with hepatoma.
Chen CY; Wu K; Lin WH; Lan TY; Wang SY; Sun JS; Weng PW; Yen RF; Yang RS
J Formos Med Assoc; 2012 Mar; 111(3):140-6. PubMed ID: 22423667
[TBL] [Abstract][Full Text] [Related]
34. Role of Tc-99m DMSA (V) scanning and serum calcitonin monitoring in the management of medullary thyroid carcinoma.
Howe TC; Padhy AK; Loke K; Magsombol B; Ng D; Goh A
Singapore Med J; 2008 Jan; 49(1):19-22. PubMed ID: 18204763
[TBL] [Abstract][Full Text] [Related]
35. Pentavalent Tc-99m DMSA scintigraphy. Prospective evaluation of its role in the management of patients with medullary carcinoma of the thyroid.
Mojiminiyi OA; Udelsman R; Soper ND; Shepstone BJ; Dudley NE
Clin Nucl Med; 1991 Apr; 16(4):259-62. PubMed ID: 1646098
[TBL] [Abstract][Full Text] [Related]
36. 99mTc-antigranulocyte bone marrow scintigraphy of breast and prostate skeletal metastases.
Limouris GS; Voliotopoulos V; Stavraka A; Vlahos L
Anticancer Res; 1997; 17(3B):1615-8. PubMed ID: 9179204
[TBL] [Abstract][Full Text] [Related]
37. Pentavalent Tc-99m dimercaptosuccinic acid imaging of hepatocellular carcinoma.
Wang SJ; Lin WY; Wey SP; Shen LH; Ting G
Neoplasma; 1999; 46(4):246-8. PubMed ID: 10613606
[TBL] [Abstract][Full Text] [Related]
38. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer.
Ito S; Kato K; Ikeda M; Iwano S; Makino N; Tadokoro M; Abe S; Nakano S; Nishino M; Ishigaki T; Naganawa S
J Nucl Med; 2007 Jun; 48(6):889-95. PubMed ID: 17504877
[TBL] [Abstract][Full Text] [Related]
39. Use of 99mTc (V) DMSA scintigraphy in the detection and localization of intestinal inflammation: comparison of findings and colonoscopy and biopsy.
Lee BF; Chiu NT; Wu DC; Tsai KB; Liu GC; Yu HS; Wang ST
Radiology; 2001 Aug; 220(2):381-5. PubMed ID: 11477240
[TBL] [Abstract][Full Text] [Related]
40. Pentavalent technetium-99m DMSA uptake in pseudofractures of osteomalacia.
Sahin M; Basoglu T; Albayrak S; Canbaz F; Yapici O
Clin Nucl Med; 2001 Jan; 26(1):62-4. PubMed ID: 11139060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
